TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25080037
Drug: Test implant
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implant
Study: 20919669
Drug: Subcutaneous closed-suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous closed-suction drainage (SCSD) applied after fascia closure, removed on postoperative day three.
Study: 20919669
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous closed-suction drainage (no-drain group).
Study: 21240151
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 400 mg/day
Study: 21240151
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 600 mg/day
Study: 21240151
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 800 mg/day
Study: 17592906
Drug: Quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine IR 400 mg/day
Study: 2821864
Drug: Ritodrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine treatment (intravenous, 2 hours prior to operation)
Study: 2821864
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (control group, same infusion rate as ritodrine)
Study: 2663239
Drug: Ketanserin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 80 mg/day
Study: 2663239
Drug: Metoprolol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 200 mg/day
Study: 25583832
Drug: dalfampridine-ER 10
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalfampridine-ER 10 mg twice daily
Study: 23362895
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with target-controlled infusion of propofol and remifentanil
Study: 19114908
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (target glycemia, 80‐110 mg/dL)
Study: 19114908
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (control group, target glycemia, 180‐200 mg/dL)
Study: 15562057
Drug: Propofol-LCT/MCT 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-LCT/MCT 1% 2 mg/kg IV
Study: 9329515
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol 24 micrograms bid for 4 weeks
Study: 3297528
Drug: Drug-resistant strains
Normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant strains
Study: 25748562
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 400 or 800 mg pretreatment with intravenous fentanyl 0.5 μg/kg (session 1) or 1.0 μg/kg (session 2)
Study: 25748562
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 400 or 800 mg pretreatment
Study: 18845283
Drug: Gynecologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynecologic treatment plus somatocognitive therapy
Study: 18845283
Drug: Standard gynecologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gynecologic treatment
Study: 9148356
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol infusion (12 to 6 mg/kg/h)
Study: 8416664
Drug: Vitamin supplement
Normalized name: Vitamin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplement (10 mg pyridoxal, 1.0 mg folic acid, 0.4 mg cyanocobalamin)
Study: 31986170
Drug: NAXOZOL (naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAXOZOL (naproxen 500 mg, esomeprazole strontium tetrahydrate 20 mg) twice per day
Study: 26338825
Drug: S10 (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: S10 (sequential therapy for 10 days)
Study: 26338825
Drug: T14 (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: T14 (triple therapy for 14 days)
Study: 22932084
Drug: Gefarnate 300
Normalized name: gefarnate
DrugBank: Gefarnate (DB12079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefarnate 300 mg daily for six weeks
Study: 22932084
Drug: Sucralfate 3
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate 3 g daily for six weeks
Study: 12074370
Drug: Medication placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication placebo (PLA)
Study: 8109654
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of trihexyphenidyl twice daily for 4 weeks
Study: 775358
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg LHRH nasal spray per day
Study: 27712095
Drug: Self‐Determination Theory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐Determination Theory (SDT) intervention designed to promote oral health care competence in an autonomy‐supportive way
Study: 22428137
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg per day oral supplementation and 2 ml (78.9 μM solution) per day topical application of astaxanthin (open-label non-controlled study)
Study: 22428137
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of astaxanthin daily supplementation (randomized double-blind placebo controlled study)
Study: 10466845
Drug: BULIT test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: BULIT test with long term clinical treatment strategy
Study: 8830062
Drug: Nefazodone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (200 mg) administered twice daily from the evening of day 2 to the morning of day 9, with triazolam (0.25 mg) on days 8 and 9.
Study: 8830062
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on days 1 and 2, with triazolam (0.25 mg) on days 8 and 9.
Study: 6235779
Drug: Toxicodendron antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicodendron antigen patch test
Study: 6235779
Drug: Delayed (96-hour)
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed (96-hour) patch test reading
Study: 23400604
Drug: Iron/folic acid
Normalized name: iron/folic acid 150 mg-1 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron/folic acid (60 mg iron)
Study: 23400604
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (30 mg iron)
Study: 11220045
Drug: Controls (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls (no medication)
Study: 11220045
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pill users with controls
Study: 20855467
Drug: DHA‐paclitaxel at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA‐paclitaxel at a starting dose of 900 mg/m(2) IV on day 1 every 3 weeks
Study: 20855467
Drug: Dacarbazine at
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine at a starting dose of 1000 mg/m(2) IV on day 1 every 3 weeks
Study: 19576297
Drug: Rectal enemas
Normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enemas (3 enemas/week, reduced by 1 enema/week every 3 months)
Study: 19576297
Drug: Oral laxatives
Normalized name: Pedia-Lax Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral laxatives (control group)
Study: 11710999
Drug: 5 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 MIU IFN-alpha s.c. daily for 32 consecutive days (IFN-alphaT group)
Study: 9135948
Drug: sulodexide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide (100 mg/day)
Study: 7957000
Drug: Codfish (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codfish (1 g fat, 23 g protein per 100 g)
Study: 7957000
Drug: Walnuts (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (64 g fat, 7 g protein, 15 g starch per 100 g)
Study: 7957000
Drug: Bananas (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bananas (22 g starch, 1 g protein per 100 g)
Study: 29143634
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 3 μg/kg of moxidectin
Study: 29143634
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive monthly doses of 3 μg/kg of moxidectin
Study: 21447866
Drug: Detectable viraemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable viraemia <15 IU/ml at week 24
Study: 21447866
Drug: Detectable viraemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable viraemia 15-<50 IU/ml at week 24
Study: 17112296
Drug: Regadenoson (CVT‐3146)
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson (CVT‐3146) at doses ranging from 0.1 to 30.0 micro g/kg
Study: 15459410
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single dose)
Study: 16212202
Drug: Ampicillin/cloxacillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/cloxacillin (3 doses)
Study: 11327628
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, p.o.)
Study: 11327628
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg, p.o.)
Study: 3821177
Drug: Aspirin (975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (975 mg three times daily)
Study: 3821177
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ethanol (maximal doses for 3 days)
Study: 3821177
Drug: Ethanol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (300 ml of 5% or 30 ml of 50% three times nightly)
Study: 25543421
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture and auricular acupressure
Study: 25543421
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride capsules (20 mg, once a day)
Study: 24045520
Drug: Timolol plus
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol plus latanoprost (fixed combination therapy)
Study: 18156457
Drug: Heparin-reduced group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-reduced group (50% reduced standard doses of nonfractionated heparin)
Study: 18156457
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (full dose of heparin)
Study: 18156457
Drug: Heparin-reduced group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-reduced group
Study: 11036880
Drug: 100 microgram
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microgram 1-thyroxine daily (Thyroxine group)
Study: 1794835
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg afloqualone
Study: 27484286
Drug: Lantus insulin
Normalized name: insulin glargine Injectable Solution [Lantus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus insulin glargine (IGlar)
Study: 17570999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of frequency doubling technology (FDT) perimetry and short-wavelength perimetry (SWAP)
Study: 17570999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FDT and SWAP
Study: 12167181
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g daily MgSO(4) infusion applied the day before surgery, just after operation, and 4 days following surgery
Study: 12167181
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g daily MgSO(4) infusion
Study: 7848024
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg twice daily
Study: 2655682
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (CBZ-C and CBZ-CR)
Study: 30782893
Drug: HORYZONS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HORYZONS plus treatment as usual (TAU)
Study: 28418763
Drug: Combined‐modality treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined‐modality treatment in HD7 (N = 627; median follow‐up, 120 months)
Study: 25219291
Drug: Current reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current reference treatments
Study: 23992914
Drug: Screening instrument
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening instrument before and at the end of radiation treatment
Study: 17305759
Drug: True eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: True eradication therapy
Study: 15242467
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg/d)
Study: 9018647
Drug: Methotrexate (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (single agent)
Study: 7876405
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg orlistat three times a day at mid-meal (group A)
Study: 7876405
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg orlistat at mid-meal and 0.5, 1, and 2 hr after mid-meal (group B)
Study: 3422693
Drug: Ceftizoxime (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (1-g single dose)
Study: 3422693
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2-g each)
Study: 30734406
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT-A)
Study: 27443596
Drug: 1-month P2Y12
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Study: 27443596
Drug: 6-month P2Y12
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Study: 23326612
Drug: Mass antibiotic
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass antibiotic distribution (specifics not provided)
Study: 21911317
Drug: Flecainide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (3 mg/kg of weight, n=40)
Study: 21911317
Drug: Amiodarone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (30 mg/kg weight, n=40)
Study: 21911317
Drug: Propafenone (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (8.5 mg/kg of weight, n=40)
Study: 15727424
Drug: Chloroquine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (150 mg daily starting 1 day after surgery)
Study: 15727424
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment without chloroquine)
Study: 8817406
Drug: Salt-restriction cilazapril
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-restriction cilazapril (2.5 mg daily)
Study: 3907278
Drug: Perphenazine decanoate
Normalized name: perphenazine decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine decanoate (PD) 100 mg intramuscularly every two weeks
Study: 3907278
Drug: Perphenazine enanthate
Normalized name: perphenazine enanthate
DrugBank: Perphenazine enanthate (DB14651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine enanthate (PE) 100 mg intramuscularly every two weeks
Study: 24762958
Drug: Molecularly targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly targeted therapy based on tumour molecular profiling
Study: 23165659
Drug: Sildenafil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil plus testosterone (10-g transdermal gel for 14 weeks)
Study: 20517210
Drug: Cortexin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin (10 mg/d intramuscular for 10 days) along with standard therapy
Study: 10360853
Drug: Propofol 20
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 20 mg (P-20)
Study: 10360853
Drug: Propofol 40
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 40 mg (P-40)
Study: 24366930
Drug: Conventional postremission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postremission therapy
Study: 22389708
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene glycol‐based bowel cleansing preparation
Study: 15734296
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral treatment (200 ml water + 100 mg danazol capsule + 3 x 500 mg paracetamol tablets + 2 x 500 mg sulfasalazine tablets)
Study: 15734296
Drug: Standard +
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard + lipid-rich meal treatment
Study: 15734296
Drug: Standard +
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard + 800 ml water treatment
Study: 11788220
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of phosphorothioate-modified 15-mer antisense ODN
Study: 10528036
Drug: Interferon gamma‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma‐1b plus prednisolone (200 microg of interferon gamma‐1b given three times per week subcutaneously and 7.5 mg of prednisolone daily)
Study: 10528036
Drug: Prednisolone alone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily)
Study: 2373132
Drug: d-sotalol (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol (0.25, 0.50, 1, 2 mg.kg‐1 i.v. and 100 mg oral dose)
Study: 2373132
Drug: dl-sotalol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-sotalol (1 mg.kg‐1 i.v.)
Study: 20032954
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (800 mg/day, serum lithium concentration 0.8-1.2 mmol/L)
Study: 20032954
Drug: Valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium (20 mg/kg/day, serum valproate concentration between 70 and 125 µg/ml)
Study: 20032954
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (800 mg/day)
Study: 20032954
Drug: Valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium (20 mg/kg/day)
Study: 11214780
Drug: Levosimendan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.5 mg four times daily for 9 days)
Study: 11214780
Drug: Levosimendan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.5 mg four times daily for 9 days) + Warfarin (25 mg single dose on the fourth treatment day)
Study: 9278211
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg single dose)
Study: 11214780
Drug: Levosimendan +
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan + Warfarin
Study: 8894790
Drug: MgO 3
Normalized name: magnesium hydroxide 13.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgO 3 times a day at a daily dose of 1.0 g (600 mg/day of magnesium)
Study: 2071263
Drug: salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmon calcitonin (sCT) nasal spray
Study: 6348587
Drug: Nadolol, 120
Normalized name: Nadolol, 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 120 mg daily
Study: 6348587
Drug: Nadolol, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 240 mg daily
Study: 21551318
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (LA) 60, 90, or 120 mg every 28 days
Study: 21551318
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (LA) 120 mg
Study: 17548021
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting glucose range of 5 to 7 mmol/L
Study: 17548021
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting glucose range of 8 to 10 mmol/L
Study: 12081234
Drug: Sequential hMG-GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential hMG-GnRH method
Study: 10443063
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once daily, adjusted to 100 mg if necessary)
Study: 10443063
Drug: Extended-release felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release felodipine (5 mg once daily, adjusted to 10 mg if necessary)
Study: 10443063
Drug: Extended-release felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release felodipine (5 mg once daily)
Study: 8991995
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid 300 mg twice daily
Study: 28145919
Drug: 1-minute rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-minute rest interval (G-1 min)